Welcome Address by the Conference Chairman
After the fruitful SHC-EASL 2017, we can reflect back on a year of extraordinary advances in viral hepatitis. For HCV, the dream of short term pangenotypic therapy is getting closer. The all oral drug regimens are now becoming a reality even in Asia but there is still considerable uncertainty about which regimens to use and in which patients. The hard to treat genotype 3 is still challenging in some situations. For HBV, treatment options using interferon and nucleos(t)ide analogues are still being explored with interesting results, but the possibility of stopping therapy in some patients leading to HBsAg seroclearance seems quite astonishing. The most exciting developments are the new therapeutic agents in clinical trial (core inhibitor, TLR7 agonists, therapeutic vaccines, siRNA) that may lead to HBsAg seroclearance, now considered to be a functional cure of HBV.
Registration fees are sustained at USD 150 per delegate !!!
With exciting internationally renowned speakers, and a very good clinically orientated programme together with case discussions, you will be completely updated on management of HCV and HBV in 2 full days. I promise you, you won’t be disappointed!!
Warmest regards and welcome to Singapore in 2018!
Professor Seng Gee Lim
Singapore Hepatology Conference